| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Ginsenoside Rh1 (Prosapogenin A2; Sanchinoside B2; Sanchinoside Rh1) is a novel and potent natural product isolated from Panax with a variety of biological activities such as enhancing memory and learning, inhibiting migration and invasion of hepatocellular carcinoma cells, decreasing adipocyte differentiation, and suppressing mast cell degranulation and anaphylaxis. Also has anti-inflammatory effects by inhibiting the expression of PPAR-γ, TNF-α, IL-6, and IL-1β.
| ln Vitro |
It was investigated how ginsenoside Rh1 affected 3T3-L1 cell adipogenesis. Lipid content in 3T3-L1 adipocytes and Oil Red O staining were used to measure how well ginsenoside Rh1 prevented adipogenesis. At 50 μM and 100 μM concentrations, ginsenoside Rh1 reduced lipogenesis by 50% and 63%, respectively. Determine the levels of expression for genes specific to adipocytes, such as PPAR-γ, C/EBP-α, FAS, and aFABP, as well as early-stage differentiation genes, such Pref-1, C/EBP-δ, and glucocorticoid receptor (GR). Following ginsenoside Rh1 treatment of 3T3-L1 cells, the mRNA of PPAR-γ, C/EBP-α, FAS, and aFABP was extracted at 18 and 24 hours, along with the mRNA of Pref-1, C/EBP-δ, and GR. Next, RT-PCR was used to examine the expression profile of genes specific to adipocytes. When compared to unstimulated adipocytes, the expression of PPAR-γ, C/EBP-α, FAS, and aFABP was considerably higher in DMI-stimulated differentiated adipocytes. On the other hand, whereas Pref-1 and C/EBP expression levels considerably decreased, treatment with DMI in the presence of ginsenoside Rh1 significantly inhibited the expression levels of PPAR-γ, C/EBP-α, FAS, and aFABP in a dose-dependent way. decline. There is no impact on δ and GR [1].
|
|---|---|
| ln Vivo |
Over the course of eight weeks, mice fed a high-fat diet (HFD) gained significantly more weight in their bodies and epididyma than mice fed a low-fat diet (LFD). However, when mice fed a high-fat diet were treated with ginsenoside Rh1, the increase in body and epididymal fat weight was significantly reduced compared with mice fed a high-fat diet. Blood levels of total cholesterol, HDL, glucose, and TG were significantly higher in the HFD-fed mouse group than they were in the LFD-fed mice group. Treatment of HFD-fed mice with ginsenoside Rh1 alone can significantly lower TG levels [1].
|
| References | |
| Additional Infomation |
(20S)-ginsenoside Rh1 is a tetracyclic triterpenoid that is (20S)-protopanaxadiol which is substituted by beta-D-glucoside at the 6alpha position. It has a role as a plant metabolite. It is a beta-D-glucoside, a 12beta-hydroxy steroid, a tetracyclic triterpenoid, a ginsenoside, a 3beta-hydroxy steroid and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane.
Ginsenoside Rh1 has been reported in Panax pseudoginseng, Gynostemma yixingense, and other organisms with data available. |
| Molecular Formula |
C36H62O9
|
|---|---|
| Molecular Weight |
638.883
|
| Exact Mass |
638.439
|
| CAS # |
63223-86-9
|
| Related CAS # |
(20R)-Ginsenoside Rh1;80952-71-2
|
| PubChem CID |
12855920
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
755.1±60.0 °C at 760 mmHg
|
| Flash Point |
410.5±32.9 °C
|
| Vapour Pressure |
0.0±5.7 mmHg at 25°C
|
| Index of Refraction |
1.581
|
| LogP |
3.74
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
45
|
| Complexity |
1110
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C)O)C)O)C
|
| InChi Key |
RAQNTCRNSXYLAH-RFCGZQMISA-N
|
| InChi Code |
InChI=1S/C36H62O9/c1-19(2)10-9-13-36(8,43)20-11-15-34(6)26(20)21(38)16-24-33(5)14-12-25(39)32(3,4)30(33)22(17-35(24,34)7)44-31-29(42)28(41)27(40)23(18-37)45-31/h10,20-31,37-43H,9,11-18H2,1-8H3/t20-,21+,22-,23+,24+,25-,26-,27+,28-,29+,30-,31+,33+,34+,35+,36-/m0/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| Synonyms |
ginsenoside Rh1 CS-3834 CS3834Prosapogenin A2 Sanchinoside B2 Sanchinoside Rh1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~156.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5652 mL | 7.8262 mL | 15.6524 mL | |
| 5 mM | 0.3130 mL | 1.5652 mL | 3.1305 mL | |
| 10 mM | 0.1565 mL | 0.7826 mL | 1.5652 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
